Open-label Trial in Parkinson's Disease (PD)
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
992actual
Sites
140
Countries
Australia, Bulgaria, Canada +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-02-24 | actual | When the study began enrolling |
| Primary completion | 2025-12-01 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-01 | actual | The whole study's end, after follow-up |
| First posted | 2021-02-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Parkinson Disease
Intervention
- Drug: Tavapadon — also filed as PF-06649751, CVL-751
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants With Treatment Emergent Adverse Events (TEAEs)
measured 62 Weeks
Number of Participants Who Discontinued Study Treatment
measured 62 Weeks
Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease Rating Scale (QUIP-RS)
measured 58 Weeks
Epworth Sleepiness Scale (ESS)
measured 58 Weeks
Columbia-Suicide Severity Rating Scale (C-SSRS)
measured 60 Weeks
Study Medication Withdrawal Questionnaire (SMWQ)
measured 60 Weeks
Change From Baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I, II and III
measured 60 Weeks
Change From Baseline in the Hauser diary
measured 58 Weeks
Change From Baseline in the EuroQol 5 Dimension 5 Level (EQ-5D-5L) Index
measured Baseline (Day 1), Weeks 32 and 58
Change From Baseline in the EuroQol 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scores (VAS)
measured Baseline (Day 1), Weeks 32 and 58
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed